Dapagliflozin + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Conditions

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Trial Timeline

Feb 8, 2017 → Jul 17, 2019

NCT ID

NCT03036124

About Dapagliflozin + Placebo

Dapagliflozin + Placebo is a phase 3 stage product being developed by AstraZeneca for Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT03036124. Target conditions include Chronic Heart Failure With Reduced Ejection Fraction (HFrEF).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04792190	Approved	Completed	Jul 27, 2021	Jun 30, 2023	Atrial Fibrillation
NCT04869124	Approved	Completed	Feb 15, 2021	Oct 28, 2024	Heart Failure，Congestive
NCT04564742	Phase 3	Completed	Dec 22, 2020	Jul 5, 2023	Acute Myocardial Infarction
NCT04363697	Approved	Completed	Sep 24, 2020	Jun 2, 2025	Acute Heart Failure
NCT04475042	Phase 2	UNKNOWN	Jul 1, 2020	May 1, 2022	Heart Failure, Diastolic
NCT02981966	Approved	Completed	May 23, 2019	May 31, 2023	Diabetes Mellitus, Type 2
NCT03619213	Phase 3	Completed	Aug 27, 2018	Mar 27, 2022	Heart Failure With Preserved Ejection Fraction
NCT03387683	Approved	Completed	Feb 28, 2018	Mar 19, 2019	Diabetes Mellitus Type 2
NCT02956811	Approved	Completed	Feb 14, 2017	Apr 2, 2019	Type 2 Diabetes
NCT03036124	Phase 3	Completed	Feb 8, 2017	Jul 17, 2019	Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT03036150	Phase 3	Completed	Feb 2, 2017	Jun 12, 2020	Chronic Kidney Disease
NCT02796170	Approved	Completed	Mar 1, 2016	Aug 1, 2020	Type 2 Diabetes
NCT02520518	Phase 2	Terminated	Aug 1, 2015	May 1, 2017	Weight Loss
NCT02459353	Approved	Completed	Aug 1, 2015	May 1, 2017	Type 2 Diabetes Mellitus
NCT02371187	Phase 2	Completed	Jun 1, 2015	Jan 1, 2018	Physical Activity
NCT02426541	Approved	Completed	Mar 23, 2015	Apr 28, 2016	Type 2 Diabetes Mellitus
NCT01392677	Phase 3	Completed	Oct 1, 2011	Aug 1, 2013	Type 2 Diabetes Mellitus
NCT01042977	Phase 3	Completed	Mar 1, 2010	Dec 1, 2012	Type 2 Diabetes Mellitus
NCT01031680	Phase 3	Completed	Feb 1, 2010	Dec 1, 2012	Type 2 Diabetes Mellitus
NCT00984867	Phase 3	Completed	Oct 1, 2009	Sep 1, 2011	Type 2 Diabetes

Competing Products

20 competing products in Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved